Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Levy, Benjamin; Barlesi, Fabrice; Paz-Ares, Luis; Bennouna, Jaafar; Erman, Mustafa; Felip, Enriqueta; Isla, Dolores; Ryun Kim, Hye; Kim, Sang-We; Madelaine, Jeannick; Molinier, Olivier; Özgüroğlu, MUSTAFA; Rodríguez Abreu, Delvys; Adeniji, Abidemi; Lorence, Robert; Voccia, Isabelle; Chisamore, Michael; Riess, Jonathan

doi:10.1016/j.lungcan.2022.01.023

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Levy B., Barlesi F., Paz-Ares L., Bennouna J., Erman M., Felip E., ...Daha Fazla

Lung cancer (Amsterdam, Netherlands), cilt.166, ss.107-113, 2022 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 166
Basım Tarihi: 2022
Doi Numarası: 10.1016/j.lungcan.2022.01.023
Dergi Adı: Lung cancer (Amsterdam, Netherlands)
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, EMBASE, MEDLINE
Sayfa Sayıları: ss.107-113
Anahtar Kelimeler: Carcinoma, Squamous Cell, Afatinib, Pembrolizumab, OPEN-LABEL, DOCETAXEL, TRIALS
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Introduction: Afatinib and pembrolizumab have separately shown survival benefit in patients with squamous cell carcinoma (SqCC) of the lung, and there is biological rationale for concurrent inhibition of the programmed death ligand-1 and epidermal growth factor receptor (EGFR) pathways in this patient population.